Adipokines: toward the molecular dissection of interactions between stromal adipocytes and breast cancer cells by Wang, Y & Fan, P
Title Adipokines: toward the molecular dissection of interactionsbetween stromal adipocytes and breast cancer cells
Author(s) Fan, P; Wang, Y
Citation
Adipokines: toward the molecular dissection of interactions
between stromal adipocytes and breast cancer cells. In Done,
Susan J. (Ed.), Breast Cancer: Recent Advances in Biology,
Imaging and Therapeutics, p. 79-102. InTech, 2011
Issued Date 2011
URL http://hdl.handle.net/10722/141469
Rights Creative Commons: Attribution 3.0 Hong Kong License
5 
Adipokines – Toward the Molecular 
Dissection of Interactions Between Stromal 
Adipocytes and Breast Cancer Cells 
Pengcheng Fan and Yu Wang* 
Department of Pharmacology and Pharmacy,  
The University of Hong Kong  
Hong Kong SAR, 
China 
1. Introduction 
After more than a half century of efforts, cancer remains the leading cause of death globally, 
second only to cardiovascular diseases. The World Health Organization estimates that 84 
million people will die from cancer in the next ten years if no action is taken 
(http://www.who.int/cancer). Obesity appears to play important roles not only in 
cardiovascular and metabolic diseases, but also in cancer etiology (Bray 2004). For example, 
overweight and obesity account for 25% of the patients with breast cancer, the most frequent 
cancer and the second leading cause of cancer death among women (Calle et al. 2003; 
McTiernan 2003). Excess adiposity over the pre- and post-menopausal years is an 
independent risk factor for breast cancer and its relapse (Alokail et al. 2009; Katoh et al. 
1994; McTiernan 2005; Saxe et al. 1999), and is associated with late-stage disease and poor 
prognosis (Lorincz and Sukumar 2006). On the other hand, information is limited on why 
excess body fat increases cancer risks and how obesity affects the prognosis and therapy of 
cancer.  
Dysfunctional adipose tissue, characterized by aberrant production of adipokines, is 
believed to be a key player in obesity-related mammary carcinogenesis. Adipokines are a 
family of molecules selectively secreted by fat tissue (Deng and Scherer 2010). In obese 
subjects, the production of adipokines is dysregulated, which in turn contributes to medical 
conditions associated with obesity (Galic et al. 2010). Evidence from clinical, epidemiological 
and experimental studies suggest that adipokines are key pathological mediators in obesity-
related cancer diseases, although the underlying mechanisms remain to be uncovered and 
may vary from site to site (Prieto-Hontoria et al. 2010; van Kruijsdijk et al. 2009). The present 
review is to provide a systemic update on how adipokines affect breast cancer cell function 
and mammary tumor initiation and development. Specifically, the detailed roles of three 
adipokines [adiponectin, lipocalin-2 and leptin] in mammary carcinogenesis will be 
discussed by integrating the information derived from cellular, animal and clinical studies. 
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The mechanistic links for each adipokine will be assembled to model the process of breast 
cancer development under obesity conditions.  
2. Stromal adipocytes in obesity-associated mammary carcinogenesis  
Mammary gland comprises of epithelial and stromal cells. Stromal tissue regulates the 
development and differentiation of breast epithelial cells (Creydt et al. 2010; Polyak and 
Kalluri 2010). Adipocyte is one of the predominant stromal cell types in the microenvironment 
of mammary tissue. Proper function of adipose tissue plays an important role in mammary 
gland development and lactation process (Couldrey et al. 2002; Wiseman and Werb 2002). 
The differentiation/redifferentiation of fat cells apparently regulates epithelial cell cycles 
and contributes to the maintenance of the mammary epithelial “niche” (Arendt et al. 2010; 
Hovey and Aimo 2010). The close relationship between adipose tissue and mammary tumor 
growth has been demonstrated by many in vitro and in vivo experimental studies (Elliott et al. 
1992; Miller et al. 1981; Sheffield and Welsch 1988). Mature adipocytes can promote the growth 
of breast carcinoma cells in a collagen gel matrix culture (Manabe et al. 2003). Co-
transplantation of tumor cells with adipocytes into mice results in increased tumor growth and 
metastasis (Iyengar et al. 2005). On the other hand, factors derived from mammary tumor 
cells stimulate the reversion of mammary adipose phenotype and promote the 
differentiation of adipose stem cells into carcinoma-associated fibroblast (Guerrero et al. 
2010; Jotzu et al. 2010). Conditioned media from breast cancer cells facilitates the 
accumulation of pre-adipocyte cells in the cancer tissue (Meng et al. 2001). 
Multiple mechanisms are implicated in linking abnormal adipose tissue with breast cancer 
development (Figure 1). First, adipocyte is the predominant stromal cell type in mammary 
tissue responsible for local estrogen production, thus contributing to the development of 
estrogen-dependent breast cancer in postmenopausal women (Sinicrope and Dannenberg 
2011). Obese women are at increased risk of developing estrogen receptor (ER)-positive 
breast cancer (Cleary and Grossmann 2009). Under obese condition, adipose tissue becomes 
“inflamed” to produce inflammatory mediators, such as tumor necrosis factor alpha (TNFα) 
and interleukin (IL)-1β, which promote the expression of cytochrome P450 aromatase, an 
enzyme responsible for the synthesis of estrogen from androgen, in adipocytes 
(Subbaramaiah et al. 2011). Second, increased fat mass in obese condition is associated with 
altered energy metabolism (McTiernan 2005). The concept of a relationship between 
dysregulated metabolism and carcinogenesis was first enunciated by Otto Warburg more 
than 80 years ago (Davison and Schafer 2010). There is now a large body of evidence 
supporting a link between obesity, metabolic syndrome, insulin resistance with increased 
risk of cancers (Vona-Davis et al. 2007; Wysocki and Wierusz-Wysocka 2010). Type 2 
diabetes and high level of circulating blood glucose have been shown to be positively 
correlated with increased breast cancer mortality (Bjorge et al. 2010; Wolf et al. 2005). Recent 
studies show that the use of metformin, an oral antidiabetic drug that has been used for 
many years, is associated with decreased cancer risk (Dowling et al. 2011). Additionally, the 
increased fat mass is associated with aberrant insulin signaling (insulin resistance) and 
increased insulin levels, which directly stimulate mammary carcinogenesis (Vona-Davis et 
al. 2007). During breast cancer progression, the composition of the extracellular matrix is 
dynamically altered and adipose tissue is critically participated in this process (Erler et al. 
2006; Fata et al. 2004).  Adipocyte-derived collagen VI could activate the pro-survival and 
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proliferation pathways to promote tumor growth and development (Iyengar et al. 2003). 
More recently, fat tissue has been recognized as an important secretory organ that can 
produce various hormones, cytokines and growth factors, collectively called adipokines 
(Galic et al. 2010). Dys-regulated expression and function of these adipokines play 
significant roles in the pathogenesis of obesity-related breast cancer diseases (Deng and 
Scherer 2010; Paz-Filho et al. 2011; Schaffler et al. 2007) (Figure 2). A number of them, 
including leptin and lipocalin-2, promote breast cancer cell survival, proliferation and tumor 
development, whereas adiponectin, the anti-inflammatory adipokine, has opposite effects 
(Jarde et al. 2011; Leng et al. 2011; Wang et al. 2007b; Yang and Moses 2009). Obese women 
with reduced serum adiponectin levels and low serum adiponectin levels are associated with 
an increased risk for breast cancer development and mortality (Duggan et al. 2011; Mantzoros 
et al. 2004). Women with higher adiponectin levels have a reduced risk of breast cancer 
(Korner et al. 2007; Miyoshi et al. 2003). Moreover, tumors in women with low serum 
adiponectin levels are more likely to show a biologically aggressive phenotype with poor 
prognosis (Miyoshi et al. 2003). The level of leptin increases in serum with increasing 
adiposity.  In women diagnosed with breast cancer, the balance of adiponectin and leptin 
has been indicated to correlate with the disease development (Grossmann et al. 2008b). 
Serum leptin to adiponectin ratio is increased significantly in breast cancer patients and 
positively correlated with tumor size (Chen et al. 2006). Adiponectin levels are negatively 
correlated with leptin, and patients with higher levels of leptin are at increased risk for late 
stage tumors (Cust et al. 2009). The reduced levels of adiponectin and elevated leptin are 
associated with lymph node metastasis (Hou et al. 2007). Another adipokine, lipocalin-2, is 
found to be associated with aggressive types of breast cancers and poor prognosis (Leng et 
al. 2011).  
 
 
 
 
Fig. 1. Multiple mechanisms are implicated in linking increased adiposity with breast cancer 
development.  
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Fig. 2. Dysregulated production of adipokines, such as leptin, lipocalin-2 and adiponectin, 
from inflamed adipose tissue, contributes to mammary tumor development through both 
indirect and direct mechanisms.   
Taken together, the above experimental and epidemiological evidences suggest that adipose 
tissue play an important role in breast cancer development and adipokines are key 
mediators linking obesity with breast cancer disease. The following sections of this chapter 
will elucidate the detailed role of adipokines, with special focus on the three adipokines, 
adiponectin, leptin and lipocalin-2, in mediating the stromal-epithelial interactions, in turn 
influencing the growth and proliferation of breast cancer cells.  
3. Adipokines as key stromal factors in regulating mammary carcinogenesis 
3.1 Adiponectin 
Adiponectin is a 30-kDa glycoprotein exclusively secreted from adipocytes (Scherer et al. 
1995). Human adiponectin gene is located on chromosome 3q27 and encodes a 244 amino 
acids polypeptide (Wang et al. 2008). Circulating concentrations of adiponectin range from 
3-30 µg/mL, accounting for ~0.05 % of total human blood proteins (Ryan et al. 2003). Unlike 
many other adipokines that are up-regulated in obesity, circulating levels of adiponectin are 
inversely associated with obesity-related disorders (Cnop et al. 2003; Pajvani and Scherer 
2003; Wang et al. 2009). 
Endogenous adiponectin is predominantly present as several characteristic oligomeric 
complexes (Wang et al. 2008). The basic building block of the adiponectin complex is a 
trimer or low molecular weight (LMW) oligomer, which is formed via hydrophobic 
interactions within its globular domain. Two trimers self-associate to form a disulfide-linked 
hexamer or middle molecular weight (MMW) oligomer, which further assembles into a 
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bouquet-like high molecular weight (HMW) multimeric complex that consists of 12-18 
monomers (Radjainia et al. 2008). Post-translational modifications, including disulfide bond 
formation at a conserved cysteine residue and glycosylations occurred on several 
hydroxylated lysine residues within the collagenous domain, are involved in the assembly 
and stabilization of the oligomeric structures (Wang et al. 2006b; Wang et al. 2005a; Wang et 
al. 2002). Different oligomeric complexes of adiponectin activate distinct signalling 
pathways and possess different biological functions.  
Two putative adiponectin receptors, termed AdipoR1 and AdipoR2, have been identified. 
Both receptors are integral membrane proteins containing seven transmembrane spanning 
domains (Yamauchi et al. 2003). They show unique distributions in various tissues and 
different affinities for the distinctive forms of circulating adiponectin. T-cadherin, which is 
highly expressed in endothelium and smooth muscle, has been identified as an adiponectin 
co-receptor with preference for hexameric and HMW adiponectin multimers (Hug et al. 
2004).   
Unlike most of the adipokines that are causally linked to obesity-related diseases, 
adiponectin has potent insulin-sensitizing, anti-inflammatory, anti-atherogenic and anti-
tumorigenic activities (Kadowaki et al. 2006; Wang et al. 2007b; Wang et al. 2008; Wang et al. 
2009). Notably, adiponectin potently inhibits the proliferation of various types of cells, 
including aortic smooth muscle cells, myelomonocytic cells, hepatic stellate cells and several 
types of cancer cells (Arita et al. 2002; Ding et al. 2005; Wang et al. 2005b; Yokota et al. 2000). 
It selectively binds to various carcinogenic growth factor and prevent the interactions of 
these growth factors to their respective receptors (Wang et al. 2005a). In addition, 
adiponectin inhibits the growth and migration of vascular endothelial cells, prevents new 
blood vessel formation, and attenuates the growth of transplanted fibrosarcoma cell tumors 
in mice (Brakenhielm et al. 2004).  
The stomal effects of adiponectin have been nicely presented in mouse models with 
spontaneous mammary tumor development. Study by Lam et al demonstrates that 
insufficient production of adiponectin in adipocyte per se promotes tumor onset and 
development in MMTV-polyomavirus middle T antigen (MMTV-PyVT) transgenic mice 
(Lam et al. 2009; Landskroner-Eiger et al. 2009). A distinctive basal-like subtype of tumors, 
characterized by high proliferative activity and unfavorable prognosis, is derived from 
adiponectin haplodeficient MMTV-PyVT mice (Lam et al. 2009). Histological analysis 
demonstrated typical morphologic features including markedly elevated geographic tumor 
necrosis, ribbon-like architecture associated with central necrosis, pushing margin of 
invasion, and stromal lymphocytic response in tumors (Livasy et al. 2007). In contrast, the 
original MMTV-PyVT mice showed a well-structured and organized morphology. In more 
advanced malignant stages, mice lacking adiponectin give rise to a larger tumor burden, an 
increase in the mobilization of circulating endothelial progenitor cells, and a gene 
expression fingerprint indicative of more aggressive tumor cells. The potent angio-mimetic 
properties of adiponectin modulate tumor vascularization and deficiency of this hormone 
creates a chronically hypoxic microenvironment (Landskroner-Eiger et al. 2009). Breast 
cancer consists of a heterogeneous group of tumors classified into five types, in which the 
HER2/neu positive and the basal type (most are ER and HER2 negative) have the worst 
clinical prognosis. Tumors derived from adiponectin haplodeficient MMTV-PyVT mice 
show a triple-negative genotype (Lam et al. 2009), which may be aroused from a different 
origin or subgroups of stem cells that develop tumor more aggressively. The origin of this 
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subtype tumor is unclear, but suggested to be the basal/myoepithelial cells, derived from 
epithelial-to-mesenchymal transition as a result of dedifferentiation, or from stem cells 
(Livasy et al. 2007).  
In human mammary tumor tissue, adiponectin mRNA expression was observed only in the 
adipose tissues. On the other hand, AdipoR1 and AdipoR2 mRNA expression was observed 
in breast cancer cells, adipose tissues and normal breast epithelial cells (Takahata et al. 
2007). In breast cancer specimen, a strong positive correlation between insulin as well as 
IGF1 receptor and AdipoR1 expression, but not AdipoR2 expression, could be observed. 
AdipoR1 is significantly higher in invasive breast cancer compared to preinvasive DCIS and 
inversely correlated with tumor size (Pfeiler et al. 2011). AdipoR2 expression is significantly 
correlated with vascular and lymphovascular invasion of breast cancer (Pfeiler et al. 2009). 
These results suggest a possibility that adiponectin might modulate the growth of normal 
breast epithelial cells and breast cancer cells directly through AdipoR1 and AdipoR2 
receptors, and that the association of low serum adiponectin levels with a high breast cancer 
risk might be explained, at least in part, by the direct effect of adiponectin on the breast 
epithelial cells. The altered expression of AdipoR1 in invasive breast cancer also suggests 
that adiponectin might exert inhibitory effects on the transformation of preinvasive to 
invasive breast cancer. Further studies are warranted to investigate the prospective 
association between the mammary adiponectin levels and the risk of obesity-related breast 
cancers in humans.  
3.2 Leptin 
Leptin is a 16-kDa protein hormone abundantly expressed in white adipose tissue (Jarde et 
al. 2011). The circulating level of leptin is in the range of 5-50 ng/ml (Garofalo and Surmacz 
2006). Obese individuals show a much higher plasma level (over 100 ng/ml) (Oksanen et al. 
1997). Leptin was originally discovered by positional cloning of the obese (ob) gene, which is 
mutated in the massively obese ob/ob mice (Zhang et al. 1994). Leptin acts in the brain to 
regulate food intake and energy expenditure (Kelesidis et al. 2011). Treatment with leptin 
significantly reduces the body weight and food intake of the ob/ob mice. The leptin receptor 
mutant db/db mice, which are phenotypically similar to ob/ob mice, do not respond to 
leptin treatment (Campfield et al. 1995). The biological activity of leptin is mediated through 
the transmembrane leptin receptor ObR, which is expressed as at least six different subtypes 
in numerous tissues and cell types. Primarily the long isoform (ObRb) is responsible for 
activating leptin signaling pathways (Ahima and Osei 2004).  
In general, higher body weight and/or obesity has been associated with shortened 
mammary tumor latency and increased incidence for development of spontaneous and 
carcinogen-induced tumors in animals (Dogan et al. 2007). In two sequential studies, 
MMTV-transforming growth factor (TGF)-α mice were crossed to genetically obese ob/ob 
and db/db mice. Surprisingly, neither type of these mice developed mammary tumors, 
suggesting that an intact leptin axis is essential for mammary tumorigenesis (Cleary et al. 
2004). On the other hand, obesity induced by high fat diet significantly increases the number 
of tumors and reduces the tumor latency in MMTV-TGF-α mice (Cleary et al. 2010). The 
involvement of leptin signaling in mammary tumorigenesis was further confirmed by a 
study using obese Zucker rats, a rat model of genetic leptin receptor deficiency. 
Administration of chemical carcinogen methylnitrosourea could only induce a smaller 
number of Zucker rats to develop mammary tumor compared to lean controls (Lee et al. 
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2001). These findings demonstrate that leptin is a growth factor to support breast cancer 
development. 
Both normal and malignant mammary tissues have been shown to produce leptin and 
express leptin receptors (Sheffield 2008). Leptin and its receptor are overexpressed in human 
breast tumor tissues (Garofalo et al. 2006). Expression of ErbB2 promotes high level 
expression of long-form leptin receptor and response to leptin. In general, the leptin/ObR 
correlates with higher tumor grade and worse prognosis (Surmacz 2007). Ishikawa et al 
observed that overexpression of both leptin and leptin receptors in breast cancer tissue are 
associated with distant metastasis (Ishikawa et al. 2004). The expression of leptin receptor 
showed a significant positive correlation with the level of leptin expression, suggesting an 
autocrine regulation of leptin expression in mammary tumor cells (Fiorio et al. 2008; 
Ishikawa et al. 2004; Revillion et al. 2006). The mRNA levels of leptin and leptin receptor are 
correlated positively with estrogen (ER) and progesterone receptors (PR), suggesting a 
possible interaction between leptin and oestrogen systems to promote breast carcinogenesis 
(Jarde et al. 2008b; Revillion et al. 2006). Analysis of human breast tumor tissues has also 
suggested an inverse relationship between leptin and adiponectin in breast cancer 
development (Jarde et al. 2008b). While leptin was expressed in a similar manner in invasive 
ductal carcinoma and in situ lesions, no tissue from in situ ductal carcinoma exhibited 
adiponectin expression. Moreover, myoepithelial cells of normal tissue adjacent to breast 
cancer exhibited 65% positivity for adiponectin while no cells in this group were positive for 
leptin expression, suggesting a possible leptin–adiponectin interaction on myoepithelial 
cells (Jarde et al. 2008b). 
3.3 Lipocalin-2 
Lipocalin-2, a 25-kDa secretory glycoprotein originally purified from human neutrophils, is 
constitutively expressed in adipose tissue (Esteve et al. 2009; Law et al. 2010). This protein 
structurally belongs to the lipocalin superfamily that shares the highly conserved structure 
of an 8-stranded antiparallel beta-barrel (Goetz et al. 2002). Circulating level of lipocalin-2 is 
elevated in obese animals and humans (Auguet et al. 2011; Hoo et al. 2008; Wang et al. 
2007a; Yan et al. 2007; Zhang et al. 2008). Clinical, animal and cellular studies demonstrate 
the causal involvement of lipocalin-2 in obesity-associated medical complications (Auguet et 
al. 2011; Catalan et al. 2009; Esteve et al. 2009; Jin et al. 2010; Kanaka-Gantenbein et al. 2008; 
Law et al. 2010; Moreno-Navarrete et al. 2010; Sommer et al. 2009; van Dam and Hu 2007; 
Yan et al. 2007; Zhang et al. 2008). In humans, the serum concentration of lipocalin-2 is 
associated closely with obesity-related anthropometric and biochemical variables, and 
represents an independent risk factor for metabolic and cardiovascular disorders (Catalan et 
al. 2009; Choi et al. 2008; Ding et al. 2010; Esteve et al. 2009; Hemdahl et al. 2006; Lee et al. 
2010; Wang et al. 2007a; Yndestad et al. 2009). Role of lipocalin-2 in regulation of cell 
proliferation, differentiation and apoptosis has been demonstrated (Devireddy et al. 2001).  
Lipocalin-2 may sequester the intracellular iron causing cell death. 
Lipocalins function to transport and present ligands to cell surface receptors and to form 
macromolecular complexes (Flower 1995). The first identified ligand of lipocalin-2 was 
bacterial catecholate-type ferric siderophores, such as enterobactin (Goetz et al. 2002). Thus 
this protein was originally considered as a potent bacteriostatic agent (Berger et al. 2006). A 
number of studies have reported that lipocalin-2 weakly binds to the tripeptide N-formyl- 
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Met-Leu-Phe (fMLF), a potent neutrophil chemoattractant, and possibly other lipophilic 
mediators of inflammation, including platelet activating factor and leukotriene B4 (Strong et 
al. 1998). Recently, chemical screens combined with crystallography and fluorescence 
detection reveal a complex of lipocalin-2 that binds iron together with a small metabolic 
product called catechol (Bao et al. 2010). The formation of the complex blocks the reactivity 
of iron, permits its transport in the circulation and facilitates recycling in endosomes. The 
lipocalin-2-catechol-Fe(III) complex represents an unforeseen endogenous siderophore for 
iron traffic in aseptic tissues. This mammalian siderophore plays a critical role in both 
cytoplasmic and mitochondrial iron homeostasis. Lacking this siderophore results in the 
accumulation of abnormally high amounts of cytoplasmic iron and elevated levels of 
reactive oxygen species (Devireddy et al. 2010). 
The promoting effects of lipocalin-2 on mammary tumor development have been signified 
by two independent studies using MMTV-ErbB2 (V664E) and MMTV-PyVT mouse models 
(Berger et al. 2010; Leng et al. 2009). Leng et al found that the initiation time of the 
mammary tumor in MMTV-ErbB2 (V664E) mice complete lacking lipocalin-2 expression 
was dramatically delayed by ~100 days compared to the mice with two copies of lipocalin-2 
alleles (Leng et al. 2009). Furthermore, the tumor burden, the number of tumors per mouse 
as well as the lung metastasis were dramatically reduced. Another study also showed 
reduced tumor weight and number of tumors per mouse in MMTV-PyVT mice lacking 
lipocalin-2 expression (Berger et al. 2010). However, there was no difference observed 
during early mammary tumorigenesis between the wild type and lipocalin-2 knockout 
group. Based on this, they concluded that lipocalin-2 played a more important role in the 
later stage of tumor development in MMTV-PyVT model, which shows a more aggressive 
phenotype with much shorter tumor latency (Berger et al. 2010). 
Positive correlations between the circulating level of lipocalin-2 and the invasive and 
metastatic status of breast cancer have been reported (Yang and Moses 2009). The expression 
patterns of lipocalin-2 in mammary tumor samples have been analyzed by a number of 
studies (Bauer et al. 2008; Stoesz et al. 1998; Yang et al. 2009). Lipocalin-2 positive cells can 
be identified in the infiltrating carcinomas but not in normal mammary tissues (Bauer et al. 
2008). High expression of lipocalin-2 correlates with low ER and PR expression, high-
histologic grade, lymph nodes metastasis, high-proliferation index and poor disease-free 
survival (Leng et al. 2011). The induced expression of lipocalin-2 staining in either the tumor 
or the stroma area is correlated with the advanced stages and the metastatic 
status. Orthotopic studies demonstrated that lipocalin-2-expressing breast tumors displayed 
a poorly differentiated phenotype and showed increased local tumor invasion and lymph 
node metastasis (Yang et al. 2009). 
In summary, animal models have provided unique tools to dissect the roles of individual 
adipokine in mammary tumor development and to elucidate the multiple pathways 
responsible for the dialogue between adipocytes and breast cancer cells. The information 
obtained from the mammary tumor models with deficient adipokine expressions 
demonstrate that in general, adipokines elicit their activities on tumor progression through 
regulating a) cancer cell transformation, proliferation and migration; b) local and systemic 
inflammation; and c) pathological angiogenesis. In addition, the role of adipokines to 
regulate systematic energy metabolism also impacts the behaviors of breast cancer cells and 
tumor development.  
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4. Signaling mechanisms responsible for the regulation of breast cancer cell 
function by adiponectin, leptin and lipocalin-2 
Although adipokines are the key players in obesity-related mammary carcinogenesis, the 
underlying mechanisms remain largely uncharacterized. Individual adipokines affect 
mammary tumor development in different manners through distinctive signalling 
pathways, with concomitant influences on proliferative, inflammatory, and metastatic 
properties of the tumor cells (Schaffler et al. 2007; Vona-Davis and Rose 2007). Moreover, the 
mechanistic networks of adipokines in mammary tumor development are usually 
intertwined with their role in regulating inflammation and angiogenesis (Lorincz and 
Sukumar 2006; Wang et al. 2007b). Here, the specific signaling mechanisms that are directly 
involved in regulating the breast cancer cell functions will be discussed and linked with 
animal and clinical presentations. 
4.1 Diversified signaling mechanisms of adiponectin: cross-talking with Wnt/-catenin 
pathway  
Adiponectin acts as an inhibitory factor for the proliferation of human breast carcinoma cells 
and mammary tumor development (Arditi et al. 2007; Dieudonne et al. 2006; Grossmann et 
al. 2008a; Hebbard et al. 2008; Jarde et al. 2008a; Kang et al. 2005; Nakayama et al. 2008; 
Pfeiler et al. 2008; Wang et al. 2006a). In vitro treatment with adiponectin at physiological 
concentrations attenuates the growth of an ER-negative human breast carcinoma MDA-MB-
231 cells by inhibiting cell proliferation and inducing apoptosis (Kang et al. 2005; Wang et al. 
2006a). It also inhibits insulin- and growth factors-stimulated proliferation in ER-positive 
human breast cancer cells (Li et al. 2011; Wang et al. 2006a). These in vitro data are supported 
by animal study demonstrating that adiponectin supplement therapy suppresses the MDA-
MB-231 breast tumor development in nude mice (Wang et al. 2006a).  
Cell-type dependent signalling mechanisms have been suggested to mediate the growth 
inhibitory effects of adiponectin (Grossmann et al. 2008a) (Figure 3). In MCF-7 cells, 
adiponectin induces AMP-activated protein kinase (AMPK) phosphorylation and 
inactivates p42/p44 MAPkinase (ERK1/2) (Dieudonne et al. 2006). By contrast, the 
inhibitory effects of adiponectin on T47D cell growth are associated with inactivation of 
ERK1/2 but not AMPK or p38 MAPK (Korner et al. 2007; Wang et al. 2006a). In MDA-MB-
231 cells with ectopic ER over-expression, globular adiponectin inhibits cell proliferation by 
blocking JNK2 signaling (Grossmann et al. 2008a). A cross-talk between adiponectin and ER 
signaling exists in breast cancer cells and that adiponectin effects on the growth and 
apoptosis of breast cancer cells in vitro are partly dependent on the presence of 17-beta 
estradiol (Pfeiler et al. 2008). In ER-negative MDA-MB-231 cells, adiponectin could modulate 
the glycogen synthase kinase-3beta (GSK3β)/-catenin signaling pathway (Wang et al. 
2006a). Prolonged treatment with adiponectin markedly reduces serum-induced 
phosphorylation of Akt and GSK3, decreases intracellular accumulation and nuclear 
translocation of -catenin, and suppresses cyclin D1 expression (Wang et al. 2006a). An 
increase of protein phosphatase 2A activity has been implicated in the dephosphorylation of 
Akt by adiponectin treatment in MDA-MB-231 cells (Kim et al. 2009). Although the effects of 
adiponectin on tumor metastasis are not conclusive, it is suggested that LKB1 is required for 
adiponectin-mediated inhibition of adhesion, migration and invasion of breast cancer cells 
(Taliaferro-Smith et al. 2009). 
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Fig. 3. Signaling pathways that mediate the anti-tumor activities of adiponectin. 
Hyperactivation of the canonical Wnt/-catenin pathway is one of the most frequent signal 
abnormalities in many types of cancers (Brown 2001; Howe and Brown 2004; Prosperi and 
Goss 2010). The central event in this pathway is the stabilization and nuclear translocation of 
-catenin, where it binds to the transcription factor TCF/LEF and consequently activates a 
cluster of genes that ultimately establish the oncogenic phenotype (Jin et al. 2008). 
Stabilization of -catenin protein and over-expression of cyclin D1 have been observed in 
over 50% of human breast tumors and increased -catenin activity was found to be 
significantly correlated with the poor prognosis of breast cancer patients (Brown 2001). 
Given the close proximity between mammary gland cells and adipocytes, decreased 
adiponectin production might be causally linked to increased -catenin accumulation and 
cyclin D1 overexpression observed in breast cancer patients. This possibility is supported by 
animal studies. The isolated mammary tumor cells from adiponectin haplodeficient MMTV-
PyVT mice are presented with hyperactivated phosphatidylinositol-3-kinase (PI3K)/Akt/β-
catenin signaling, which at least partly attributes to the decreased phosphatase and tensin 
homolog (PTEN) activities (Lam et al. 2009). PTEN is one of the most frequently mutated 
tumor suppressors that can prevent the activation of the cell survival PI3K/Akt signaling 
pathway (Carnero et al. 2008). In MMTV-PyVT animals with reduced production of 
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adiponectin, PTEN is inactivated by a redox-regulated mechanism involving thioredoxin 
and thioredoxin reductase. Specificity protein 1, a redox-regulated transcription factor, is 
involved in mediating the effects of adiponectin to stimulate the expression of Wnt 
inhibitory factor-1, a Wnt antagonist frequently silenced in human breast tumors (Liu et al. 
2008). In summary, these findings have not only suggested a cross-talk between adiponectin 
and Wnt signaling pathway, but also provided a novel mechanistic insight to explain how 
metabolic alterations in adiponectin haplodeficient tumor may gain a survival advantage. 
4.2 Leptin-mediated signaling in breast cancer cells: in relation to other mitogenic 
receptors 
Leptin acts as a mitogen and survival factor for human breast cancer cells (Markowska et al. 
2004). Leptin receptors are expressed in various human breast cancer cell lines and in 
human primary breast carcinoma (Frankenberry et al. 2006; Garofalo et al. 2006; Hu et al. 
2002; Laud et al. 2002; Sheffield 2008). Leptin acts through multifaceted signaling pathways, 
including Jak2/STAT3 (Janus kinase 2/signal transducer and activator of transcription 3), 
PI3K/Akt, ERK1/2 and SOCS3 (Fusco et al. 2010; Palianopoulou et al. 2011; Saxena et al. 
2007; Yin et al. 2004). Different sensitivities to recombinant leptin treatment have been found 
in distinctive breast carcinoma cell lines. For example, in MCF 7 cells, leptin induces a strong 
phosphorylation of STAT3 and ERK1/2, leading to an increased cell viability and 
proliferation (Fusco et al. 2010). This response is not present in MDA-MB 231 cells, in which 
leptin potentiates the anti-proliferative action of cAMP elevating agents by concurring to 
cell cycle arrest at G1 phase and inducing apoptosis (Naviglio et al. 2009). 
Leptin induces the expression of vascular endothelial growth factor (VEGF) in both human 
and mouse mammary tumor cells, and promotes angiogenesis, which is related to the worse 
prognosis of breast cancer (Zhou et al. 2011). HIF-1alpha and NFkappaB are implicated in 
leptin-regulated VEGF expression through both canonic (MAPK, PI-3K) and non-canonic 
(PKC, JNK and p38 MAP) signalling pathways (Gonzalez-Perez et al. 2010). Leptin contributes 
to the elevated circulating estrogen levels in obese women. It stimulates aromatase activity in 
adipose stromal cells at high concentrations (Magoffin et al. 1999). The action of leptin to 
enhance the promoter activity of aromatase is mediated by AP-1 in MCF-7 cells (Catalano et al. 
2003). These evidence suggest that elevated leptin concentrations may cause locally 
augmented VEGF and estrogen in the breast and thereby promote tumor formation. 
Leptin exerts its activity not only through its own receptors, but also through crosstalks with 
other signaling systems implicated in tumorigenesis (Ozbay and Nahta 2008). Co-treatment 
of leptin and insulin-like growth factor (IGF)-I significantly increases proliferation as well as 
invasion and migration of breast cancer cells (Saxena et al. 2008). A bidirectional crosstalk 
between leptin and IGF-I signaling exists to synergistically activate the downstream 
effectors, Akt and ERK1/2. Moreover, leptin and IGF-I treatment transactivates epidermal 
growth factor receptor (EGFR) to induce invasion and migration of breast cancer cells. In 
breast cancer cell lines, HER2 and ObR are coexpressed and physically interacted (Fiorio et 
al. 2008; Ray et al. 2007). Leptin treatment increases HER2 phosphorylation on Tyr 1248 
(Fiorio et al. 2008). Coexpression of HER2 and the leptin/ObR system might contribute to 
enhanced HER2 activity and reduced sensitivity to anti-HER2 treatments. These data 
suggest indicate the possibility of using EGFR inhibitors to counter the pro-cancerous effects 
of leptin and IGF-I in breast cancers. Exogenous leptin induces tyrosine phosphorylation of 
HER2 in SKBR3 cells, which showed marked overexpression of HER2. Leptin-induced 
HER2 phosphorylation was partially reduced by an EGFR inhibitor, AG1478, or a Jak 
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inhibitor, AG490. Moreover, leptin-induced phosphorylation of ERK1/2 could be abrogated 
by a HER2 tyrosine kinase inhibitor, AG825 (Soma et al. 2008). In fact, the influence of leptin 
on breast cancer development not only relates to the presence or absence of HER2 but also 
depends on ER status (Ray et al. 2007). Knocking down of ERalpha attenuates leptin-
induced activation of STAT3, whereas the enhancement of leptin-mediated STAT3 activity is 
independent of ERalpha ligands. ERalpha binding to STAT3 and Jak2 might lead to an 
increased ERalpha-dependent cell viability(Binai et al. 2010). Leptin plays important role in 
enhancing in situ estradiol production and promoting estrogen-dependent breast cancer 
progression. The ability of leptin to transactivate ERalpha and mimic the classic features of 
ERalpha signaling has been observed in MCF-7 breast cancer cell line. MAPK pathway is 
found to be involved in this process. Moreover, estradiol-induced activation of ERalpha can 
be potentiated by leptin exposure (Catalano et al. 2004).  
Taken together, these findings suggest that the leptin system plays an important role in 
breast cancer pathogenesis and progression, and that it represents a novel target for 
therapeutic intervention in breast cancer disease (Cirillo et al. 2008). 
4.3 Lipocalin-2: Controversies and role in epithelial to mesenchymal transition 
Lipocalin-2 is a putative in vivo estrogen target gene and paracrine factor that mediates the 
growth regulatory effects of estrogen in normal breast epithelium (Seth et al. 2002). It 
contains an ER response element in its promoter. On the other hand, in T47D breast cancer 
cells, hormone treatment decreases the mRNA expression of lipocalin-2 (Mrusek et al. 2005), 
suggesting that normal and cancerous estrogen receptor-positive cells are distinct at the 
molecular level. Elevated lipocalin-2 may influence the steroid status of the mammary 
epithelial cells. When ectopically introducing lipocalin-2 into MCF-7 cells, their ER-
dependent tumor growth in the xenografted mice is lost and the tumor cells become ER-
negative (Yang et al. 2009). These data imply that modulation of lipocalin-2 expression may 
enable the breast cancer cells to become sensitive to ER therapy, a result that might be 
translated into clinical usage for ER-targeted therapy. 
Both human and mouse mammary tumor cell lines have been used to examine the 
importance of lipocalin-2 in mammary tumor formation. Overexpression of lipocalin-2 in 
mouse 4T1 and human MDA-MB-468 cells greatly promoted their ability in cell migration 
and invasion (Leng et al. 2009; Shi et al. 2008). Moreover, implantation of 4T1 or MDA-MB-
468 cells ectopically expressing lipocalin-2 generated a significant more number of lung 
metastatic nodules compared to those implanted with the unmodified cells. The lung 
metastasis could be blocked by injection of a polyclonal antibody against lipocalin-2 (Leng et 
al. 2009). In HER2-positive human breast cancer cell line SKBR3, knocking down lipocalin-2 
expression reduced the migration and in and ER-positive MCF-7 cells, These findings are 
consistent with the study by Fougere et al suggesting that the anti-migration activity of 
NFAT3 is through inhibition of lipocalin-2 gene expression (Fougere et al. 2010). In human 
tissue and urine samples, lipocalin-2 levels are consistently associated with invasive breast 
cancer (Yang et al. 2009). 
Lipocalin-2 has been shown to induce the epithelial to mesenchymal transition (EMT) in 
breast cancer cells (Leng et al. 2011). Cells undergone EMT show increased motility and 
invasiveness as well as elevated lipocalin-2 expression. When ectopically expressed in MCF-
7 cells, lipocalin-2 induces a typical EMT change of the cell morphology, accompanied by a 
loss of epithelial marker (E-cadherin) and an increased expression of the mesenchymal 
markers (vimentin and fibronectin) (Yang et al. 2009). Lipocalin-2 silencing in aggressive 
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breast cancer cells inhibits cell migration and the mesenchymal phenotype. Increased 
secretion of lipocalin-2 from the tumor cells might directly affect MMP-9 activity to promote 
cell motility or the transition to a more mesenchymal/aggressive phenotype (Leng et al. 
2011). Much higher blood gelatinase activities are found in the tumor-bearing MMTV-
ErbB mice with normal lipocalin-2 expression than those deficient of lipocalin-2 expression 
(Leng et al. 2009). ERalpha is also suggested to participate in lipocalin-2-induced EMT. By 
contrast, in 4T1 cells lipocalin-2 appears to reverse the EMT process induced by Ras 
expression (Hanai et al. 2005). Different phases or sites of lipocalin-2 treatment have been 
suggested for these controversial findings. During EMT, the initial increased lipocalin-2 
stimulates epithelial migration and the elevated exogenous lipocalin-2 may facilitate the 
recovery (Mori et al. 2005; Yang et al. 2002).  
In summary, although lipocalin-2 regulates EMT, one of the key processes involved in 
tumor progression and metastasis, the underlying mechanisms remain to be further 
elucidated.  
5. Concluding remarks 
The prevalence of obesity and its associated diseases has posed a huge healthcare impact on 
our society. During the past two decades, a panel of adipokines critically involved in 
pathological processes of obesity-associated breast cancer diseases has been discovered. 
Their contributions to the development of breast cancer and the underlying mechanisms are 
divergent. For example, adiponectin deficiency is associated with an accelerated mammary 
tumor development and altered Wnt/-catenin signaling. On the other hand, the tumors of 
mice without lipocalin-2 are less metastatic and show slower rate of growth. Clearly, 
individual adipokines are able to modulate specific oncogenic and metabolic pathways, 
which synergistically promote or antagonize the development of breast cancer disease 
under obese conditions. The three adipokines discussed in this chapter not only represent 
potential therapeutic targets for breast cancer, but can also serve as biomarkers for early 
diagnosis and disease prevention. Compounds related to leptin that may have therapeutic 
use are currently being investigated in pre-clinical studies (Gonzalez et al. 2006; Ray and 
Cleary 2010; Rene Gonzalez et al. 2009; Surmacz 2007). Continued research will 
undoubtedly provide more insights into the relationship between adipose tissue-derived 
factors and breast cancer development, as well as the ways to intervene these interactions.  
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